Holen Sie sich die Stockscreener-App
65.14
0.65%
0.42
Handel nachbörslich:
65.14
Schlusskurs vom Vortag:
$64.72
Offen:
$65
24-Stunden-Volumen:
1.11M
Relative Volume:
2.31
Marktkapitalisierung:
$3.27B
Einnahmen:
$379.25M
Nettoeinkommen (Verlust:
$-77.34M
KGV:
-40.40
EPS:
-1.6122
Netto-Cashflow:
$-27.87M
1W Leistung:
+22.01%
1M Leistung:
+23.70%
6M Leistung:
+28.48%
1J Leistung:
+58.53%
1-Tages-Spanne:
$64.07
$65.98
1-Wochen-Bereich:
$54.74
$67.45
52-Wochen-Spanne:
$36.86
$67.45
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Vergleichen Sie MIRM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
65.14 | 3.25B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals’ SWOT analysis: rare disease biotech stock shows promise - Investing.com
Mirum Pharma CEO Peetz sells $2.48 million in shares By Investing.com - Investing.com Canada
Mirum Pharma CFO Eric Bjerkholt sells $524k in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $89.00 at Evercore ISI - MarketBeat
Mirum Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingReal Trader Watchlist of Hot Stocks Released - 선데이타임즈
Is Mirum Pharmaceuticals Inc. forming bullish engulfing patternsBest 5x Return Trade Entries - thegnnews.com
Stifel Initiates Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Announces Target Price $89 - 富途牛牛
Mirum's Meteoric Surge: What's Fueling the 9.38% Intraday Rally? - AInvest
HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Mirum’s Financial Rocket: Soaring Figures, Intriguing Questions - StocksToTrade
Mirum Soars 10% on Analyst Upgrades and Pipeline Catalysts: Is This the Start of a Biotech Breakout? - AInvest
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates - simplywall.st
Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) - Seeking Alpha
Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Delivers Growth With Orphan Liver Drug Success - Finimize
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript - MSN
Insider Selling at Mirum Pharmaceuticals: A Signal of Confidence or Caution for Long-Term Investors? - AInvest
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $66 to $89 - 富途牛牛
BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James - TipRanks
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance - TipRanks
Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio - AInvest
Citizens JMP Raises Mirum Pharmaceuticals Price Target to $81, Maintains Outperform Rating - AInvest
MIRM Stock Flying High: Too Late to Buy? - StocksToTrade
Mirum Pharmaceuticals shares rise 12.83% intraday after reporting strong Q2 results and raising 2025 guidance. - AInvest
MIRM Stock Up On Q2 Earnings And Revenue Beat, Raised 2025 View - Barchart.com
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP - TipRanks
Mirum Soars 10.5% on Earnings Beat and Revenue Surge: A Biotech Breakout in the Making? - AInvest
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD - Investing.com
Mirum: JMP Securities Raises PT to $81, Maintains Market Outperform - AInvest
Mirum:Raymond James raises PT to $82, maintains Strong Buy rating. - AInvest
Mirum Pharmaceuticals stock price target raised to $80 from $73 at H.C. Wainwright - Investing.com Canada
Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright - TipRanks
Mirum:HC Wainwright Raises PT to $80, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals stock price target raised to $81 by JMP - Investing.com South Africa
Mirum 2025 Q2 Earnings Losses Narrow Significantly - AInvest
Earnings call transcript: Mirum Pharmaceuticals sees revenue boost in Q2 2025 - Investing.com
Mirum Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Mirum Pharmaceuticals Q2 2025: Unpacking Contradictions on Market Penetration, Sales Growth, and Clinical Strategy - AInvest
Mirum Pharmaceuticals Reports Q2 2025 Earnings and Business Update - AInvest
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals soars as revenue crushes estimates By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals soars as revenue crushes estimates - Investing.com
Mirum Pharmaceuticals earnings beat by $0.21, revenue topped estimates - Investing.com Canada
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c) - TipRanks
Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q2 Revenue $127.8M, vs. FactSet Est of $108.1M - MarketScreener
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals Q2 2025 Earnings Preview: EPS Estimate $-0.33, Revenue Estimate $108.1M. - AInvest
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):